The Healthium Medtech Date Will Be Updated Soon .
Healthism Medtech is a multinational medical technology firm specialising in chronic, post-surgery, and surgical care. The company’s vision is to provide every patient worldwide access to precision medical technology products.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
Coming Soon
Price Range
₹0 per share
Face Value
₹0 per share
GMP
₹0
Healthium Medtech GMP
The Healthium Medtech IPO GMP is ₹[].
IPO Overview
Healthium Medtech Ltd, the country’s second-largest medical consumables and surgical sutures company, has filed draft papers with SEBI to raise funds via an initial public offering (IPO) worth Rs. 390 crores and an offer for sale of up to 39.10 million shares by existing shareholders and promoters. The OFS will comprise the sale of 39 million shares by Quinag Acquisition (FDI) and up to 100,000 shares by Mahadevan Narayanamoni. Currently, Quinag Acquisition FDI holds a 99.79% stake in the firm.
Healthium Medtech IPO Financials
| Particulars | 2021 | 2020 | 2019 |
| Revenue from operations (₹ million) | 7,133.57 | 6,391.79 | 5,840.20 |
| Restated profit before tax (₹ million) | 1,130.33 | 578.81 | 243.04 |
| Restated profit for the year (₹ million) | 854.28 | 367.60 | 137.31 |
| Gross margin (%) | 62.33% | 65.89% | 65.26% |
| EBITDA (₹) | 1,539.27 | 955.74 | 544.27 |
| EBITDA margin (%) | 21.58% | 14.95% | 9.32% |
| ROE (%) | 21.57% | 10.98% | 3.57% |
| ROCE (%) | 22.98% | 16.08% | 6.45% |
| Cash conversion cycle (in days) | 139 | 171 | 219 |
| Net cash flow from operating activities (₹ million) | 1,221.29 | 589.24 | 514.38 |
Company Profile
The brand has a fantastic commercial presence and market access in India and the UK. They export goods to more than 80 nations, including South America, Asia, and America, as well as the US, UK, Germany, and France (established markets). The brand stands out from its competitors because of its extensive selection of high-quality products at enticing prices. The company’s quality and value proposition aligns with the focus of healthcare stakeholders such as governments, hospitals, payers and surgeons on improving the affordability of and access to quality healthcare. Further, its well-established corporate and product brands and relationships with hospitals, surgeons and distributors create competitive advantages for its business.
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
